Joya Chandra
- Hematology top 2%
- Acute Myeloid Leukemia Research 17
- Chronic Myeloid Leukemia Treatments 17
- Molecular Biology top 2%
- Histone Deacetylase Inhibitors Research 27
- Cell death mechanisms and regulation 18
- Protein Degradation and Inhibitors 15
- Genetics top 2%
- Chronic Lymphocytic Leukemia Research 14
- Oncology top 5%
- Immunology top 5%
-
- Childhood Cancer Survivors' Quality of Life 22
-
- Acute Lymphoblastic Leukemia research 14
- Co-authors
- Sten OrreniusAfshin SamaliDavid J. McConkeyClaudia P. MillerKanchugarakoppal S. RangappaMary E. IrwinMichael A. PalladinoC. T. Sadashiva
- Cited by
- HematologyMolecular BiologyGenetics
- Partner nations
- United StatesIndiaSweden
In The Last Decade
Joya Chandra
152 papers receiving 5.8k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Hematology 548
- Molecular Biology 3.3k
- Genetics 479
- Oncology 964
- Immunology 727
Countries citing papers authored by Joya Chandra
This map shows the geographic impact of Joya Chandra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joya Chandra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joya Chandra more than expected).
Fields of papers citing papers by Joya Chandra
This network shows the impact of papers produced by Joya Chandra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joya Chandra. The network helps show where Joya Chandra may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Joya Chandra, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2023 | 6 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 2 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 25 | |
| 7 | 2021 | 6 | |
| 8 | 2020 | 8 | |
| 9 | 2020 | 9 | |
| 10 | 2019 | 9 | |
| 11 | 2015 | 17 | |
| 12 | 2015 | 17 | |
| 13 | 2011 | 70 | |
| 14 | 2009 | 127 | |
| 15 | In vitro antioxidant and anticholinesterase activity of Acorus calamus and Nardostachys jatamansi rhizomes. | 2009 | 14 |
| 16 | Overlapping functional activities of proteasome inhibitor, NPI-0052, and HDAC inhibitors contribute to synergistic cytotoxicity in leukemia cells | 2008 | 1 |
| 17 | 2006 | 16 | |
| 18 | 2002 | 209 | |
| 19 | 2002 | 167 | |
| 20 | 2000 | 45 |
About Joya Chandra
Joya Chandra is a scholar working on Hematology, Genetics and Molecular Biology, having authored 159 papers that have together received 5.9k indexed citations. Recurring topics across this work include Histone Deacetylase Inhibitors Research (27 papers), Childhood Cancer Survivors' Quality of Life (22 papers), Cell death mechanisms and regulation (18 papers), Acute Myeloid Leukemia Research (17 papers), Chronic Myeloid Leukemia Treatments (17 papers), Protein Degradation and Inhibitors (15 papers), Chronic Lymphocytic Leukemia Research (14 papers) and Acute Lymphoblastic Leukemia research (14 papers). The work is most often cited by research in Hematology (548 citations), Molecular Biology (3.3k citations) and Genetics (479 citations). Joya Chandra has collaborated with scholars based in United States, India and Sweden. Frequent co-authors include Sten Orrenius, Afshin Samali, David J. McConkey, Claudia P. Miller, Kanchugarakoppal S. Rangappa, Mary E. Irwin, Michael A. Palladino, C. T. Sadashiva, Richard J. Bold and Michael J. Keating. Their work appears in journals such as Blood, Neuro-Oncology, Cancer Research, Journal of Biological Chemistry and Bioorganic & Medicinal Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.